Report cover image

Friedreich Ataxia Drug Industry Research Report 2025

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 132 Pages
SKU # APRC20543027

Description

Summary

According to APO Research, the global Friedreich Ataxia Drug market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Friedreich Ataxia Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Friedreich Ataxia Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Friedreich Ataxia Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Friedreich Ataxia Drug include Takeda, Pfizer Inc, Voyager Therapeutics Inc, STATegics Inc, Retrotope Inc, Reata Pharmaceuticals Inc, RaNA Therapeutics Inc, ProQR Therapeutics NV and Ixchel Pharma LLC, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Friedreich Ataxia Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Friedreich Ataxia Drug.

The report will help the Friedreich Ataxia Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The Friedreich Ataxia Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Friedreich Ataxia Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Friedreich Ataxia Drug Segment by Company

Takeda
Pfizer Inc
Voyager Therapeutics Inc
STATegics Inc
Retrotope Inc
Reata Pharmaceuticals Inc
RaNA Therapeutics Inc
ProQR Therapeutics NV
Ixchel Pharma LLC
Forward Pharma A/S
Catabasis Pharmaceuticals, Inc.
Cardero Therapeutics Inc
Biovista Inc.
BioMarin Pharmaceutical Inc.
Adverum Biotechnologies Inc
Friedreich Ataxia Drug Segment by Type

BVA-202
BHV-4157
AGIL-FA
ADVM-063
Others
Friedreich Ataxia Drug Segment by Application

Clinic
Hospital
Others
Friedreich Ataxia Drug Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Friedreich Ataxia Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Friedreich Ataxia Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Friedreich Ataxia Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Friedreich Ataxia Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Friedreich Ataxia Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Friedreich Ataxia Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Table of Contents

132 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Friedreich Ataxia Drug Market Size (2020-2031)
2.2.2 Global Friedreich Ataxia Drug Sales (2020-2031)
2.2.3 Global Friedreich Ataxia Drug Market Average Price (2020-2031)
2.3 Friedreich Ataxia Drug by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 BVA-202
2.3.3 BHV-4157
2.3.4 AGIL-FA
2.3.5 ADVM-063
2.3.6 Others
2.4 Friedreich Ataxia Drug by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 Clinic
2.4.3 Hospital
2.4.4 Others
3 Market Competitive Landscape by Manufacturers
3.1 Global Friedreich Ataxia Drug Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global Friedreich Ataxia Drug Sales (K Units) of Manufacturers (2020-2025)
3.3 Global Friedreich Ataxia Drug Revenue of Manufacturers (2020-2025)
3.4 Global Friedreich Ataxia Drug Average Price by Manufacturers (2020-2025)
3.5 Global Friedreich Ataxia Drug Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of Friedreich Ataxia Drug, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Friedreich Ataxia Drug, Product Type & Application
3.8 Global Manufacturers of Friedreich Ataxia Drug, Established Date
3.9 Global Friedreich Ataxia Drug Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Takeda
4.1.1 Takeda Company Information
4.1.2 Takeda Business Overview
4.1.3 Takeda Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2020-2025)
4.1.4 Takeda Friedreich Ataxia Drug Product Portfolio
4.1.5 Takeda Recent Developments
4.2 Pfizer Inc
4.2.1 Pfizer Inc Company Information
4.2.2 Pfizer Inc Business Overview
4.2.3 Pfizer Inc Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2020-2025)
4.2.4 Pfizer Inc Friedreich Ataxia Drug Product Portfolio
4.2.5 Pfizer Inc Recent Developments
4.3 Voyager Therapeutics Inc
4.3.1 Voyager Therapeutics Inc Company Information
4.3.2 Voyager Therapeutics Inc Business Overview
4.3.3 Voyager Therapeutics Inc Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2020-2025)
4.3.4 Voyager Therapeutics Inc Friedreich Ataxia Drug Product Portfolio
4.3.5 Voyager Therapeutics Inc Recent Developments
4.4 STATegics Inc
4.4.1 STATegics Inc Company Information
4.4.2 STATegics Inc Business Overview
4.4.3 STATegics Inc Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2020-2025)
4.4.4 STATegics Inc Friedreich Ataxia Drug Product Portfolio
4.4.5 STATegics Inc Recent Developments
4.5 Retrotope Inc
4.5.1 Retrotope Inc Company Information
4.5.2 Retrotope Inc Business Overview
4.5.3 Retrotope Inc Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2020-2025)
4.5.4 Retrotope Inc Friedreich Ataxia Drug Product Portfolio
4.5.5 Retrotope Inc Recent Developments
4.6 Reata Pharmaceuticals Inc
4.6.1 Reata Pharmaceuticals Inc Company Information
4.6.2 Reata Pharmaceuticals Inc Business Overview
4.6.3 Reata Pharmaceuticals Inc Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2020-2025)
4.6.4 Reata Pharmaceuticals Inc Friedreich Ataxia Drug Product Portfolio
4.6.5 Reata Pharmaceuticals Inc Recent Developments
4.7 RaNA Therapeutics Inc
4.7.1 RaNA Therapeutics Inc Company Information
4.7.2 RaNA Therapeutics Inc Business Overview
4.7.3 RaNA Therapeutics Inc Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2020-2025)
4.7.4 RaNA Therapeutics Inc Friedreich Ataxia Drug Product Portfolio
4.7.5 RaNA Therapeutics Inc Recent Developments
4.8 ProQR Therapeutics NV
4.8.1 ProQR Therapeutics NV Company Information
4.8.2 ProQR Therapeutics NV Business Overview
4.8.3 ProQR Therapeutics NV Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2020-2025)
4.8.4 ProQR Therapeutics NV Friedreich Ataxia Drug Product Portfolio
4.8.5 ProQR Therapeutics NV Recent Developments
4.9 Ixchel Pharma LLC
4.9.1 Ixchel Pharma LLC Company Information
4.9.2 Ixchel Pharma LLC Business Overview
4.9.3 Ixchel Pharma LLC Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2020-2025)
4.9.4 Ixchel Pharma LLC Friedreich Ataxia Drug Product Portfolio
4.9.5 Ixchel Pharma LLC Recent Developments
4.10 Forward Pharma A/S
4.10.1 Forward Pharma A/S Company Information
4.10.2 Forward Pharma A/S Business Overview
4.10.3 Forward Pharma A/S Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2020-2025)
4.10.4 Forward Pharma A/S Friedreich Ataxia Drug Product Portfolio
4.10.5 Forward Pharma A/S Recent Developments
4.11 Catabasis Pharmaceuticals, Inc.
4.11.1 Catabasis Pharmaceuticals, Inc. Company Information
4.11.2 Catabasis Pharmaceuticals, Inc. Business Overview
4.11.3 Catabasis Pharmaceuticals, Inc. Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2020-2025)
4.11.4 Catabasis Pharmaceuticals, Inc. Friedreich Ataxia Drug Product Portfolio
4.11.5 Catabasis Pharmaceuticals, Inc. Recent Developments
4.12 Cardero Therapeutics Inc
4.12.1 Cardero Therapeutics Inc Company Information
4.12.2 Cardero Therapeutics Inc Business Overview
4.12.3 Cardero Therapeutics Inc Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2020-2025)
4.12.4 Cardero Therapeutics Inc Friedreich Ataxia Drug Product Portfolio
4.12.5 Cardero Therapeutics Inc Recent Developments
4.13 Biovista Inc.
4.13.1 Biovista Inc. Company Information
4.13.2 Biovista Inc. Business Overview
4.13.3 Biovista Inc. Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2020-2025)
4.13.4 Biovista Inc. Friedreich Ataxia Drug Product Portfolio
4.13.5 Biovista Inc. Recent Developments
4.14 BioMarin Pharmaceutical Inc.
4.14.1 BioMarin Pharmaceutical Inc. Company Information
4.14.2 BioMarin Pharmaceutical Inc. Business Overview
4.14.3 BioMarin Pharmaceutical Inc. Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2020-2025)
4.14.4 BioMarin Pharmaceutical Inc. Friedreich Ataxia Drug Product Portfolio
4.14.5 BioMarin Pharmaceutical Inc. Recent Developments
4.15 Adverum Biotechnologies Inc
4.15.1 Adverum Biotechnologies Inc Company Information
4.15.2 Adverum Biotechnologies Inc Business Overview
4.15.3 Adverum Biotechnologies Inc Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2020-2025)
4.15.4 Adverum Biotechnologies Inc Friedreich Ataxia Drug Product Portfolio
4.15.5 Adverum Biotechnologies Inc Recent Developments
5 Global Friedreich Ataxia Drug Market Scenario by Region
5.1 Global Friedreich Ataxia Drug Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global Friedreich Ataxia Drug Sales by Region: 2020-2031
5.2.1 Global Friedreich Ataxia Drug Sales by Region: 2020-2025
5.2.2 Global Friedreich Ataxia Drug Sales by Region: 2026-2031
5.3 Global Friedreich Ataxia Drug Revenue by Region: 2020-2031
5.3.1 Global Friedreich Ataxia Drug Revenue by Region: 2020-2025
5.3.2 Global Friedreich Ataxia Drug Revenue by Region: 2026-2031
5.4 North America Friedreich Ataxia Drug Market Facts & Figures by Country
5.4.1 North America Friedreich Ataxia Drug Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America Friedreich Ataxia Drug Sales by Country (2020-2031)
5.4.3 North America Friedreich Ataxia Drug Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.5 Europe Friedreich Ataxia Drug Market Facts & Figures by Country
5.5.1 Europe Friedreich Ataxia Drug Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe Friedreich Ataxia Drug Sales by Country (2020-2031)
5.5.3 Europe Friedreich Ataxia Drug Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Netherlands
5.6 Asia Pacific Friedreich Ataxia Drug Market Facts & Figures by Country
5.6.1 Asia Pacific Friedreich Ataxia Drug Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific Friedreich Ataxia Drug Sales by Country (2020-2031)
5.6.3 Asia Pacific Friedreich Ataxia Drug Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Southeast Asia
5.7 South America Friedreich Ataxia Drug Market Facts & Figures by Country
5.7.1 South America Friedreich Ataxia Drug Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America Friedreich Ataxia Drug Sales by Country (2020-2031)
5.7.3 South America Friedreich Ataxia Drug Revenue by Country (2020-2031)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa Friedreich Ataxia Drug Market Facts & Figures by Country
5.8.1 Middle East and Africa Friedreich Ataxia Drug Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa Friedreich Ataxia Drug Sales by Country (2020-2031)
5.8.3 Middle East and Africa Friedreich Ataxia Drug Revenue by Country (2020-2031)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 Segment by Type
6.1 Global Friedreich Ataxia Drug Sales by Type (2020-2031)
6.1.1 Global Friedreich Ataxia Drug Sales by Type (2020-2031) & (K Units)
6.1.2 Global Friedreich Ataxia Drug Sales Market Share by Type (2020-2031)
6.2 Global Friedreich Ataxia Drug Revenue by Type (2020-2031)
6.2.1 Global Friedreich Ataxia Drug Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global Friedreich Ataxia Drug Revenue Market Share by Type (2020-2031)
6.3 Global Friedreich Ataxia Drug Price by Type (2020-2031)
7 Segment by Application
7.1 Global Friedreich Ataxia Drug Sales by Application (2020-2031)
7.1.1 Global Friedreich Ataxia Drug Sales by Application (2020-2031) & (K Units)
7.1.2 Global Friedreich Ataxia Drug Sales Market Share by Application (2020-2031)
7.2 Global Friedreich Ataxia Drug Revenue by Application (2020-2031)
7.2.1 Global Friedreich Ataxia Drug Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global Friedreich Ataxia Drug Revenue Market Share by Application (2020-2031)
7.3 Global Friedreich Ataxia Drug Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Friedreich Ataxia Drug Value Chain Analysis
8.1.1 Friedreich Ataxia Drug Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Friedreich Ataxia Drug Production Mode & Process
8.2 Friedreich Ataxia Drug Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Friedreich Ataxia Drug Distributors
8.2.3 Friedreich Ataxia Drug Customers
9 Global Friedreich Ataxia Drug Analyzing Market Dynamics
9.1 Friedreich Ataxia Drug Industry Trends
9.2 Friedreich Ataxia Drug Industry Drivers
9.3 Friedreich Ataxia Drug Industry Opportunities and Challenges
9.4 Friedreich Ataxia Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
Table 5. Global Friedreich Ataxia Drug Volume and Revenue Market Size and CAGR of Manufacturers (2020 Versus 2024)
Table 6. Global Friedreich Ataxia Drug Sales (K Units) of Manufacturers (2020-2025)
Table 7. Global Friedreich Ataxia Drug Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Friedreich Ataxia Drug Revenue of Manufacturers (2020-2025)
Table 9. Global Friedreich Ataxia Drug Revenue Share by Manufacturers (2020-2025)
Table 10. Global Market Friedreich Ataxia Drug Average Price (US$/Unit) of Manufacturers (2020-2025)
Table 11. Global Friedreich Ataxia Drug Industry Ranking, 2023 VS 2024 VS 2025
Table 12. Global Manufacturers of Friedreich Ataxia Drug, Manufacturing Sites & Headquarters
Table 13. Global Manufacturers of Friedreich Ataxia Drug, Product Type & Application
Table 14. Global Friedreich Ataxia Drug Manufacturers Established Date
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Friedreich Ataxia Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 18. Takeda Company Information
Table 19. Takeda Business Overview
Table 20. Takeda Friedreich Ataxia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 21. Takeda Friedreich Ataxia Drug Product Portfolio
Table 22. Takeda Recent Developments
Table 23. Pfizer Inc Company Information
Table 24. Pfizer Inc Business Overview
Table 25. Pfizer Inc Friedreich Ataxia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 26. Pfizer Inc Friedreich Ataxia Drug Product Portfolio
Table 27. Pfizer Inc Recent Developments
Table 28. Voyager Therapeutics Inc Company Information
Table 29. Voyager Therapeutics Inc Business Overview
Table 30. Voyager Therapeutics Inc Friedreich Ataxia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 31. Voyager Therapeutics Inc Friedreich Ataxia Drug Product Portfolio
Table 32. Voyager Therapeutics Inc Recent Developments
Table 33. STATegics Inc Company Information
Table 34. STATegics Inc Business Overview
Table 35. STATegics Inc Friedreich Ataxia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 36. STATegics Inc Friedreich Ataxia Drug Product Portfolio
Table 37. STATegics Inc Recent Developments
Table 38. Retrotope Inc Company Information
Table 39. Retrotope Inc Business Overview
Table 40. Retrotope Inc Friedreich Ataxia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 41. Retrotope Inc Friedreich Ataxia Drug Product Portfolio
Table 42. Retrotope Inc Recent Developments
Table 43. Reata Pharmaceuticals Inc Company Information
Table 44. Reata Pharmaceuticals Inc Business Overview
Table 45. Reata Pharmaceuticals Inc Friedreich Ataxia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 46. Reata Pharmaceuticals Inc Friedreich Ataxia Drug Product Portfolio
Table 47. Reata Pharmaceuticals Inc Recent Developments
Table 48. RaNA Therapeutics Inc Company Information
Table 49. RaNA Therapeutics Inc Business Overview
Table 50. RaNA Therapeutics Inc Friedreich Ataxia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 51. RaNA Therapeutics Inc Friedreich Ataxia Drug Product Portfolio
Table 52. RaNA Therapeutics Inc Recent Developments
Table 53. ProQR Therapeutics NV Company Information
Table 54. ProQR Therapeutics NV Business Overview
Table 55. ProQR Therapeutics NV Friedreich Ataxia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 56. ProQR Therapeutics NV Friedreich Ataxia Drug Product Portfolio
Table 57. ProQR Therapeutics NV Recent Developments
Table 58. Ixchel Pharma LLC Company Information
Table 59. Ixchel Pharma LLC Business Overview
Table 60. Ixchel Pharma LLC Friedreich Ataxia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 61. Ixchel Pharma LLC Friedreich Ataxia Drug Product Portfolio
Table 62. Ixchel Pharma LLC Recent Developments
Table 63. Forward Pharma A/S Company Information
Table 64. Forward Pharma A/S Business Overview
Table 65. Forward Pharma A/S Friedreich Ataxia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 66. Forward Pharma A/S Friedreich Ataxia Drug Product Portfolio
Table 67. Forward Pharma A/S Recent Developments
Table 68. Catabasis Pharmaceuticals, Inc. Company Information
Table 69. Catabasis Pharmaceuticals, Inc. Business Overview
Table 70. Catabasis Pharmaceuticals, Inc. Friedreich Ataxia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 71. Catabasis Pharmaceuticals, Inc. Friedreich Ataxia Drug Product Portfolio
Table 72. Catabasis Pharmaceuticals, Inc. Recent Developments
Table 73. Cardero Therapeutics Inc Company Information
Table 74. Cardero Therapeutics Inc Business Overview
Table 75. Cardero Therapeutics Inc Friedreich Ataxia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 76. Cardero Therapeutics Inc Friedreich Ataxia Drug Product Portfolio
Table 77. Cardero Therapeutics Inc Recent Developments
Table 78. Biovista Inc. Company Information
Table 79. Biovista Inc. Business Overview
Table 80. Biovista Inc. Friedreich Ataxia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Biovista Inc. Friedreich Ataxia Drug Product Portfolio
Table 82. Biovista Inc. Recent Developments
Table 83. BioMarin Pharmaceutical Inc. Company Information
Table 84. BioMarin Pharmaceutical Inc. Business Overview
Table 85. BioMarin Pharmaceutical Inc. Friedreich Ataxia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 86. BioMarin Pharmaceutical Inc. Friedreich Ataxia Drug Product Portfolio
Table 87. BioMarin Pharmaceutical Inc. Recent Developments
Table 88. Adverum Biotechnologies Inc Company Information
Table 89. Adverum Biotechnologies Inc Business Overview
Table 90. Adverum Biotechnologies Inc Friedreich Ataxia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 91. Adverum Biotechnologies Inc Friedreich Ataxia Drug Product Portfolio
Table 92. Adverum Biotechnologies Inc Recent Developments
Table 93. Global Friedreich Ataxia Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 94. Global Friedreich Ataxia Drug Sales by Region (2020-2025) & (K Units)
Table 95. Global Friedreich Ataxia Drug Sales Market Share by Region (2020-2025)
Table 96. Global Friedreich Ataxia Drug Sales by Region (2026-2031) & (K Units)
Table 97. Global Friedreich Ataxia Drug Sales Market Share by Region (2026-2031)
Table 98. Global Friedreich Ataxia Drug Revenue by Region (2020-2025) & (US$ Million)
Table 99. Global Friedreich Ataxia Drug Revenue Market Share by Region (2020-2025)
Table 100. Global Friedreich Ataxia Drug Revenue by Region (2026-2031) & (US$ Million)
Table 101. Global Friedreich Ataxia Drug Revenue Market Share by Region (2026-2031)
Table 102. North America Friedreich Ataxia Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 103. North America Friedreich Ataxia Drug Sales by Country (2020-2025) & (K Units)
Table 104. North America Friedreich Ataxia Drug Sales by Country (2026-2031) & (K Units)
Table 105. North America Friedreich Ataxia Drug Revenue by Country (2020-2025) & (US$ Million)
Table 106. North America Friedreich Ataxia Drug Revenue by Country (2026-2031) & (US$ Million)
Table 107. Europe Friedreich Ataxia Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 108. Europe Friedreich Ataxia Drug Sales by Country (2020-2025) & (K Units)
Table 109. Europe Friedreich Ataxia Drug Sales by Country (2026-2031) & (K Units)
Table 110. Europe Friedreich Ataxia Drug Revenue by Country (2020-2025) & (US$ Million)
Table 111. Europe Friedreich Ataxia Drug Revenue by Country (2026-2031) & (US$ Million)
Table 112. Asia Pacific Friedreich Ataxia Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 113. Asia Pacific Friedreich Ataxia Drug Sales by Country (2020-2025) & (K Units)
Table 114. Asia Pacific Friedreich Ataxia Drug Sales by Country (2026-2031) & (K Units)
Table 115. Asia Pacific Friedreich Ataxia Drug Revenue by Country (2020-2025) & (US$ Million)
Table 116. Asia Pacific Friedreich Ataxia Drug Revenue by Country (2026-2031) & (US$ Million)
Table 117. South America Friedreich Ataxia Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 118. South America Friedreich Ataxia Drug Sales by Country (2020-2025) & (K Units)
Table 119. South America Friedreich Ataxia Drug Sales by Country (2026-2031) & (K Units)
Table 120. South America Friedreich Ataxia Drug Revenue by Country (2020-2025) & (US$ Million)
Table 121. South America Friedreich Ataxia Drug Revenue by Country (2026-2031) & (US$ Million)
Table 122. Middle East and Africa Friedreich Ataxia Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 123. Middle East and Africa Friedreich Ataxia Drug Sales by Country (2020-2025) & (K Units)
Table 124. Middle East and Africa Friedreich Ataxia Drug Sales by Country (2026-2031) & (K Units)
Table 125. Middle East and Africa Friedreich Ataxia Drug Revenue by Country (2020-2025) & (US$ Million)
Table 126. Middle East and Africa Friedreich Ataxia Drug Revenue by Country (2026-2031) & (US$ Million)
Table 127. Global Friedreich Ataxia Drug Sales by Type (2020-2025) & (K Units)
Table 128. Global Friedreich Ataxia Drug Sales by Type (2026-2031) & (K Units)
Table 129. Global Friedreich Ataxia Drug Sales Market Share by Type (2020-2025)
Table 130. Global Friedreich Ataxia Drug Sales Market Share by Type (2026-2031)
Table 131. Global Friedreich Ataxia Drug Revenue by Type (2020-2025) & (US$ Million)
Table 132. Global Friedreich Ataxia Drug Revenue by Type (2026-2031) & (US$ Million)
Table 133. Global Friedreich Ataxia Drug Revenue Market Share by Type (2020-2025)
Table 134. Global Friedreich Ataxia Drug Revenue Market Share by Type (2026-2031)
Table 135. Global Friedreich Ataxia Drug Price by Type (2020-2025) & (US$/Unit)
Table 136. Global Friedreich Ataxia Drug Price by Type (2026-2031) & (US$/Unit)
Table 137. Global Friedreich Ataxia Drug Sales by Application (2020-2025) & (K Units)
Table 138. Global Friedreich Ataxia Drug Sales by Application (2026-2031) & (K Units)
Table 139. Global Friedreich Ataxia Drug Sales Market Share by Application (2020-2025)
Table 140. Global Friedreich Ataxia Drug Sales Market Share by Application (2026-2031)
Table 141. Global Friedreich Ataxia Drug Revenue by Application (2020-2025) & (US$ Million)
Table 142. Global Friedreich Ataxia Drug Revenue by Application (2026-2031) & (US$ Million)
Table 143. Global Friedreich Ataxia Drug Revenue Market Share by Application (2020-2025)
Table 144. Global Friedreich Ataxia Drug Revenue Market Share by Application (2026-2031)
Table 145. Global Friedreich Ataxia Drug Price by Application (2020-2025) & (US$/Unit)
Table 146. Global Friedreich Ataxia Drug Price by Application (2026-2031) & (US$/Unit)
Table 147. Key Raw Materials
Table 148. Raw Materials Key Suppliers
Table 149. Friedreich Ataxia Drug Distributors List
Table 150. Friedreich Ataxia Drug Customers List
Table 151. Friedreich Ataxia Drug Industry Trends
Table 152. Friedreich Ataxia Drug Industry Drivers
Table 153. Friedreich Ataxia Drug Industry Restraints
Table 154. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Friedreich Ataxia Drug Product Image
Figure 5. Global Friedreich Ataxia Drug Revenue (US$ Million), 2020 VS 2024 VS 2031
Figure 6. Global Friedreich Ataxia Drug Market Size (2020-2031) & (US$ Million)
Figure 7. Global Friedreich Ataxia Drug Sales (2020-2031) & (K Units)
Figure 8. Global Friedreich Ataxia Drug Average Price (US$/Unit) & (2020-2031)
Figure 9. BVA-202 Product Image
Figure 10. BHV-4157 Product Image
Figure 11. AGIL-FA Product Image
Figure 12. ADVM-063 Product Image
Figure 13. Others Product Image
Figure 14. Clinic Product Image
Figure 15. Hospital Product Image
Figure 16. Others Product Image
Figure 17. Global Friedreich Ataxia Drug Revenue Share by Manufacturers in 2024
Figure 18. Global Manufacturers of Friedreich Ataxia Drug, Manufacturing Sites & Headquarters
Figure 19. Global Top 5 and 10 Friedreich Ataxia Drug Players Market Share by Revenue in 2024
Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 21. Global Friedreich Ataxia Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 22. Global Friedreich Ataxia Drug Sales by Region in 2024
Figure 23. Global Friedreich Ataxia Drug Revenue by Region in 2024
Figure 24. North America Friedreich Ataxia Drug Market Size by Country in 2024
Figure 25. North America Friedreich Ataxia Drug Sales Market Share by Country (2020-2031)
Figure 26. North America Friedreich Ataxia Drug Revenue Market Share by Country (2020-2031)
Figure 27. United States Friedreich Ataxia Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 28. Canada Friedreich Ataxia Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. Europe Friedreich Ataxia Drug Market Size by Country in 2024
Figure 30. Europe Friedreich Ataxia Drug Sales Market Share by Country (2020-2031)
Figure 31. Europe Friedreich Ataxia Drug Revenue Market Share by Country (2020-2031)
Figure 32. Germany Friedreich Ataxia Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. France Friedreich Ataxia Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. U.K. Friedreich Ataxia Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Italy Friedreich Ataxia Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Netherlands Friedreich Ataxia Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. Asia Pacific Friedreich Ataxia Drug Market Size by Country in 2024
Figure 38. Asia Pacific Friedreich Ataxia Drug Sales Market Share by Country (2020-2031)
Figure 39. Asia Pacific Friedreich Ataxia Drug Revenue Market Share by Country (2020-2031)
Figure 40. China Friedreich Ataxia Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Japan Friedreich Ataxia Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. South Korea Friedreich Ataxia Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. India Friedreich Ataxia Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Australia Friedreich Ataxia Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. China Taiwan Friedreich Ataxia Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Southeast Asia Friedreich Ataxia Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Southeast Asia Friedreich Ataxia Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. South America Friedreich Ataxia Drug Market Size by Country in 2024
Figure 49. South America Friedreich Ataxia Drug Sales Market Share by Country (2020-2031)
Figure 50. South America Friedreich Ataxia Drug Revenue Market Share by Country (2020-2031)
Figure 51. Mexico Friedreich Ataxia Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Brazil Friedreich Ataxia Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Argentina Friedreich Ataxia Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. Middle East and Africa Friedreich Ataxia Drug Market Size by Country in 2024
Figure 55. Middle East and Africa Friedreich Ataxia Drug Sales Market Share by Country (2020-2031)
Figure 56. Middle East and Africa Friedreich Ataxia Drug Revenue Market Share by Country (2020-2031)
Figure 57. Turkey Friedreich Ataxia Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 58. Saudi Arabia Friedreich Ataxia Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 59. UAE Friedreich Ataxia Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 60. Global Friedreich Ataxia Drug Sales Market Share by Type (2020-2031)
Figure 61. Global Friedreich Ataxia Drug Revenue Market Share by Type (2020-2031)
Figure 62. Global Friedreich Ataxia Drug Price (US$/Unit) by Type (2020-2031)
Figure 63. Global Friedreich Ataxia Drug Sales Market Share by Application (2020-2031)
Figure 64. Global Friedreich Ataxia Drug Revenue Market Share by Application (2020-2031)
Figure 65. Global Friedreich Ataxia Drug Price (US$/Unit) by Application (2020-2031)
Figure 66. Friedreich Ataxia Drug Value Chain
Figure 67. Friedreich Ataxia Drug Production Mode & Process
Figure 68. Direct Comparison with Distribution Share
Figure 69. Distributors Profiles
Figure 70. Friedreich Ataxia Drug Industry Opportunities and Challenges
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.